The global demand for ePrescribing Market is presumed to reach the market size of nearly USD 15.95 Billion by 2032 from USD 3.07 Billion in 2023 with a CAGR of 20.09% under the study period 2024 - 2032.
ePrescribing, short for electronic prescribing, is a digital healthcare technology enabling healthcare providers to generate and transmit prescriptions to pharmacies directly from their electronic health record (EHR) systems or electronic prescribing software. This process eliminates the need for paper-based prescriptions, reducing errors, improving efficiency, and enhancing patient safety. It allows healthcare providers to access patient medication histories, screen for drug interactions, and send prescriptions securely to pharmacies, streamlining the medication management process. Additionally, it promotes better coordination of care among healthcare providers and facilitates medication adherence by patients, leading to improved healthcare outcomes and medication management efficiency.
MARKET DYNAMICS
The digitization of healthcare systems and adopting electronic health records (EHRs) drive the demand for electronic prescribing solutions. Healthcare professionals increasingly acknowledge the benefits of ePrescribing, such as improved medication safety, enhanced efficiency, and reduced medication errors. Additionally, government initiatives and regulations promoting ePrescribing systems to improve patient care, reduce healthcare costs, and combat prescription drug abuse fuel market growth. Moreover, integrating ePrescribing solutions with pharmacy systems, electronic medical records, and clinical decision support tools expands their functionality and usability, driving adoption among healthcare providers. Furthermore, the COVID-19 pandemic has hastened the adoption of telehealth and remote healthcare services, creating opportunities for vendors to offer integrated telemedicine solutions. Technological advancements such as mobile applications, electronic prior authorization capabilities, and interoperability standards contribute to market growth. However, interoperability issues and concerns about data security may challenge the market growth in the coming years.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of eprescribing. The growth and trends of eprescribing industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the eprescribing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the ePrescribing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the ePrescribing market include Allscripts Healthcare, LLC, Athenahealth, Change Healthcare, DrFirst, Epic Systems Corporation, McKesson Corporation, Networking Technology, Inc., NXGN Management, LLC, Practice Fusion, Inc., Surescripts. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
3.7.2 Market Attractiveness Analysis By Delivery Mode
3.7.3 Market Attractiveness Analysis By Substances
3.7.4 Market Attractiveness Analysis By Usage
3.7.5 Market Attractiveness Analysis By Specialties
3.7.6 Market Attractiveness Analysis By End-use
3.7.7 Market Attractiveness Analysis By Region
4. VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1 List of Raw Materials
4.2.2 Raw Material Manufactures List
4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1 Direct Marketing
4.4.2 Indirect Marketing
4.4.3 Marketing Channel Development Trend
5. GLOBAL EPRESCRIBING MARKET ANALYSIS BY PRODUCT
5.1. Overview By Product
5.2. Historical and Forecast Data
5.3. Analysis By Product
5.4. Solutions (Integrated Solutions, Standalone Solutions) Historic and Forecast Sales By Regions
5.5. Services (Support, Implementation, Training, Network) Historic and Forecast Sales By Regions
6. GLOBAL EPRESCRIBING MARKET ANALYSIS BY DELIVERY MODE
6.1. Overview By Delivery Mode
6.2. Historical and Forecast Data
6.3. Analysis By Delivery Mode
6.4. Web/Cloud-Based Historic and Forecast Sales By Regions
6.5. On-Premises Historic and Forecast Sales By Regions
7. GLOBAL EPRESCRIBING MARKET ANALYSIS BY SUBSTANCES
7.1. Overview By Substances
7.2. Historical and Forecast Data
7.3. Analysis By Substances
7.4. Controlled Substances Historic and Forecast Sales By Regions
7.5. Non-Controlled Substances Historic and Forecast Sales By Regions
8. GLOBAL EPRESCRIBING MARKET ANALYSIS BY USAGE
8.1. Overview By Usage
8.2. Historical and Forecast Data
8.3. Analysis By Usage
8.4. Handheld Historic and Forecast Sales By Regions
8.5. Computer-Based Devices Historic and Forecast Sales By Regions
9. GLOBAL EPRESCRIBING MARKET ANALYSIS BY SPECIALTIES
9.1. Overview By Specialties
9.2. Historical and Forecast Data
9.3. Analysis By Specialties
9.4. Oncology Historic and Forecast Sales By Regions
9.5. Sports Medicine Historic and Forecast Sales By Regions
9.6. Neurology Historic and Forecast Sales By Regions
9.7. Cardiology Historic and Forecast Sales By Regions
9.8. Other Historic and Forecast Sales By Regions
10. GLOBAL EPRESCRIBING MARKET ANALYSIS BY END-USE
10.1. Overview By End-use
10.2. Historical and Forecast Data
10.3. Analysis By End-use
10.4. Hospital Historic and Forecast Sales By Regions
10.5. Office-Based Physicians Historic and Forecast Sales By Regions
10.6. Pharmacy Historic and Forecast Sales By Regions
10.7. Other Historic and Forecast Sales By Regions
11. GLOBAL EPRESCRIBING MARKET ANALYSIS BY GEOGRAPHY
11.1. Regional Outlook
11.2. Introduction
11.3. North America Sales Analysis
11.3.1 Overview, Historic and Forecast Data Sales Analysis
11.3.2 North America By Segment Sales Analysis
11.3.3 North America By Country Sales Analysis
11.3.4 United States Sales Analysis
11.3.5 Canada Sales Analysis
11.3.6 Mexico Sales Analysis
11.4. Europe Sales Analysis
11.4.1 Overview, Historic and Forecast Data Sales Analysis
11.4.2 Europe By Segment Sales Analysis
11.4.3 Europe By Country Sales Analysis
11.4.4 United Kingdom Sales Analysis
11.4.5 France Sales Analysis
11.4.6 Germany Sales Analysis
11.4.7 Italy Sales Analysis
11.4.8 Russia Sales Analysis
11.4.9 Rest Of Europe Sales Analysis
11.5. Asia Pacific Sales Analysis
11.5.1 Overview, Historic and Forecast Data Sales Analysis
11.5.2 Asia Pacific By Segment Sales Analysis
11.5.3 Asia Pacific By Country Sales Analysis
11.5.4 China Sales Analysis
11.5.5 India Sales Analysis
11.5.6 Japan Sales Analysis
11.5.7 South Korea Sales Analysis
11.5.8 Australia Sales Analysis
11.5.9 South East Asia Sales Analysis
11.5.10 Rest Of Asia Pacific Sales Analysis
11.6. Latin America Sales Analysis
11.6.1 Overview, Historic and Forecast Data Sales Analysis
11.6.2 Latin America By Segment Sales Analysis
11.6.3 Latin America By Country Sales Analysis
11.6.4 Brazil Sales Analysis
11.6.5 Argentina Sales Analysis
11.6.6 Peru Sales Analysis
11.6.7 Chile Sales Analysis
11.6.8 Rest of Latin America Sales Analysis
11.7. Middle East & Africa Sales Analysis
11.7.1 Overview, Historic and Forecast Data Sales Analysis
11.7.2 Middle East & Africa By Segment Sales Analysis
11.7.3 Middle East & Africa By Country Sales Analysis
11.7.4 Saudi Arabia Sales Analysis
11.7.5 UAE Sales Analysis
11.7.6 Israel Sales Analysis
11.7.7 South Africa Sales Analysis
11.7.8 Rest Of Middle East And Africa Sales Analysis
12. COMPETITIVE LANDSCAPE OF THE EPRESCRIBING COMPANIES
12.1. EPrescribing Market Competition
12.2. Partnership/Collaboration/Agreement
12.3. Merger And Acquisitions
12.4. New Product Launch
12.5. Other Developments
13. COMPANY PROFILES OF EPRESCRIBING INDUSTRY
13.1. Top Companies Market Share Analysis
13.2. Market Concentration Rate
13.3. Allscripts Healthcare LLC
13.3.1 Company Overview
13.3.2 Company Revenue
13.3.3 Products
13.3.4 Recent Developments
13.4. Athenahealth
13.4.1 Company Overview
13.4.2 Company Revenue
13.4.3 Products
13.4.4 Recent Developments
13.5. Change Healthcare
13.5.1 Company Overview
13.5.2 Company Revenue
13.5.3 Products
13.5.4 Recent Developments
13.6. DrFirst
13.6.1 Company Overview
13.6.2 Company Revenue
13.6.3 Products
13.6.4 Recent Developments
13.7. Epic Systems Corporation
13.7.1 Company Overview
13.7.2 Company Revenue
13.7.3 Products
13.7.4 Recent Developments
13.8. McKesson Corporation
13.8.1 Company Overview
13.8.2 Company Revenue
13.8.3 Products
13.8.4 Recent Developments
13.9. Networking Technology Inc.
13.9.1 Company Overview
13.9.2 Company Revenue
13.9.3 Products
13.9.4 Recent Developments
13.10. NXGN Management LLC
13.10.1 Company Overview
13.10.2 Company Revenue
13.10.3 Products
13.10.4 Recent Developments
13.11. Practice Fusion Inc.
13.11.1 Company Overview
13.11.2 Company Revenue
13.11.3 Products
13.11.4 Recent Developments
13.12. Surescripts.
13.12.1 Company Overview
13.12.2 Company Revenue
13.12.3 Products
13.12.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies